T1	Participants 0 50	Selenium Treatment and Chagasic Cardiopathy (STCC)
T2	Participants 71 114	a double-blind randomized controlled trial.
T3	Participants 163 219	30% of patients with chronic Trypanosoma cruzi infection
T4	Participants 345 489	patients with Chagas heart disease have lower Se levels than healthy individuals and patients with T. cruzi infection without of cardiac disease
T5	Participants 827 995	(1) a Chagas disease diagnosis confirmed by serology; (2) segmental, mild or moderate global left ventricular systolic dysfunction; and (3) age between 18 and 65 years.
T6	Participants 1035 1212	(1) pregnancy, (2) diabetes mellitus, (3) tobacco use, (4) alcohol abuse, (5) evidence of nonchagasic heart disease, (6) depression, (7) dysphagia with evidence of food residues
T7	Participants 1408 1490	100 Î¼g of sodium selenite once daily for 365 consecutive days compared to placebo.
T8	Participants 1878 1996	One hundred thirty patients will be randomly allocated into either the intervention or placebo group at a ratio of 1:1
T9	Participants 2163 2231	n blinded to the intervention groups during the 5 years of follow-up
T10	Participants 2373 2445	the therapeutic regimen for this neglected tropical disease at low cost.
T11	Participants 2481 2533	gov ID: NCT00875173 (registered 20 October 20 2008).
